abhishreshthaa
New member
SWOT ANALYSIS ON Allergan Inc : Allergan, Inc., is a global specialty pharmaceutical company. Their product ranges include ophthalmic pharmaceuticals, dermatology products, and neurological products.
The company's most notable neurologic product is Botox, used around the world to treat a variety of debilitating disorders associated with muscle overactivity and also well-known—under the trade names Botox Cosmetic and Vistabel—for the treatment of facial lines.
Its most important manufacturing plants are in Waco, Texas; Westport, Ireland; and San Jose, Costa Rica.
Strengths
The company's most notable neurologic product is Botox, used around the world to treat a variety of debilitating disorders associated with muscle overactivity and also well-known—under the trade names Botox Cosmetic and Vistabel—for the treatment of facial lines.
Its most important manufacturing plants are in Waco, Texas; Westport, Ireland; and San Jose, Costa Rica.
Strengths
- Industry leaders
- Strong sales and marketing infrastructure
- Revived blockbuster credentials in recent years - Lyrica, Sutent and Chantix/Champix
- Strong R&D departments
- R&D innovation with a broad therapeutic coverage
- Marketing strength in major geographical and therapeutic areas
- Existing Patent protection for a number of years on key products
jews
Weaknesses
* Drought in blockbuster launches between
1999 and 2004 (masked by M&A activity)
* Entrenchment in low growth therapy area
markets such as CV and CNS
* Very limited penetration of biologics market
* Discontinuation of products in the latter stages of development
* Co-marketing agreements can limit Pfizer's global presence
Opportunities
* Restructuring strategy designed to cut costs and create a leaner company
* Funding available to facilitate product/company
* Acquisitions and in-licensing/co- development opportunities
* Biologic market expansion
* Decreasing development time through favorable R&D collaborations and internal efforts
* Emergence of integrated global markets and globalisation for new products
* Co-marketing agreements with companies wishing to capitalize on Pfizer's marketing
* Strengths, providing Pfizer with strong products and therefore revenue growth
Threats
* Considerable exposure to generic competition, focal point of which is Lipitor, due to lose patent exclusivity in 2011
* Further large scale M&A activity could further decline Pfizer's profitability
* Increased competition for core products like Viagra as its high cost encourages use of cheaper alternative treatments
* An increase in the number of safety issues surrounding Viagra
* Competition from products similar to Pfizer's in R&D that reach the market close to or before Pfizer's products
* The new economic potential of emergent China, India and competition in diverse regional markets.
* Economic downturn influencing consumers' purchasing power
* Negative publicity
Last edited by a moderator: